Search | Clinical Trials Finder

Conditions: Hepatitis A
Interventions: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 18
States / cities: Centennial, Colorado • Bardstown, Kentucky • Louisville, Kentucky + 13 more

Conditions: Meningitis, Meningococcal
Interventions: Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Months to 2 Months
Enrollment: 4,545 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 53
States / cities: Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more

Conditions: Rotavirus Infection, Rotavirus Vaccines
Interventions: Rotarix, Pediarix, Hiberix, Prevenar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more

Conditions: Hepatitis A
Interventions: hepatitis A vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 6 Months to 25 Years
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 2
States / cities: Anchorage, Alaska

Conditions: Meningitis, Meningococcal Infection
Interventions: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 365 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 3
States / cities: San Diego, California • Aurora, Colorado • Indianapolis, Indiana

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 19 Months
Enrollment: 950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 45
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Hepatitis A
Interventions: Havrix™, Infanrix™, ActHIB™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 22
States / cities: Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more

Conditions: Fever After Vaccination, Fever, Seizures Fever
Interventions: mRNA COVID-19 Vaccine, Routine Childhood Vaccinations; Biological
Lead sponsor: Duke University; Other
Eligibility: 6 Months to 4 Years
Enrollment: 347 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Oakland, California • Atlanta, Georgia • New York, New York + 2 more

Conditions: Healthy Subjects
Interventions: MGD010, Placebo, Hepatitis A vaccine; Drug · Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis A
Interventions: Havrix®, M-M-R®II, VARIVAX®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 42
States / cities: Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more

Conditions: Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions: Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 15 Months
Enrollment: 852 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 49
States / cities: Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 15
States / cities: Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Healthy
Interventions: Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day to 49 Years
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 120
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 56 more

Conditions: HIV Infections
Interventions: Tetanus toxoid, Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more

Conditions: HIV Infections
Interventions: Tetanus Toxoid Vaccine, Hepatitis A Vaccine (Inactivated), HIV-1 Immunogen, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 2
States / cities: Iowa City, Iowa • New York, New York

Conditions: Pneumococcal Infections
Interventions: Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions: Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 585 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more

Conditions: Childhood Cancer, Multiple Diseases
Interventions: Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more

Conditions: Apnea, Apnea Neonatal, Prematurity
Interventions: PCV13, DTaP, HBV, IPV, Hib; Biological
Lead sponsor: Duke University; Other
Eligibility: 6 Weeks and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more

Search by objective public record fields.

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

Phase 1 Study of MGD010 in Healthy Subjects

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Increasing HAART-Induced Immune Restoration With Cyclosporine

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Effects of Aging on Primary and Secondary Vaccine Responses

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life